Amylyx Pharmaceuticals Statistics
Share Statistics
Amylyx Pharmaceuticals has 89.14M
shares outstanding. The number of shares has increased by 30.29%
in one year.
Shares Outstanding | 89.14M |
Shares Change (YoY) | 30.29% |
Shares Change (QoQ) | 29.26% |
Owned by Institutions (%) | 73.12% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 1,672 |
FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 4.97M, so 5.58% of the outstanding
shares have been sold short.
Short Interest | 4.97M |
Short % of Shares Out | 5.58% |
Short % of Float | 6.16% |
Short Ratio (days to cover) | 4.43 |
Valuation Ratios
The PE ratio is -0.85 and the forward
PE ratio is -3.68.
Amylyx Pharmaceuticals's PEG ratio is
0.
PE Ratio | -0.85 |
Forward PE | -3.68 |
PS Ratio | 2.95 |
Forward PS | 2.8 |
PB Ratio | 1.56 |
P/FCF Ratio | -1.53 |
PEG Ratio | 0 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Amylyx Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.67,
with a Debt / Equity ratio of 0.01.
Current Ratio | 6.67 |
Quick Ratio | 6.67 |
Debt / Equity | 0.01 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $710,333.33 |
Profits Per Employee | $-2,453,195.12 |
Employee Count | 123 |
Asset Turnover | 0.45 |
Inventory Turnover | n/a |
Taxes
Income Tax | -393K |
Effective Tax Rate | 0.13% |
Stock Price Statistics
The stock price has increased by 198.26% in the
last 52 weeks. The beta is -0.59, so Amylyx Pharmaceuticals's
price volatility has been lower than the market average.
Beta | -0.59 |
52-Week Price Change | 198.26% |
50-Day Moving Average | 4.41 |
200-Day Moving Average | 3.95 |
Relative Strength Index (RSI) | 56.51 |
Average Volume (20 Days) | 926,667 |
Income Statement
In the last 12 months, Amylyx Pharmaceuticals had revenue of 87.37M
and earned -301.74M
in profits. Earnings per share was -4.43.
Revenue | 87.37M |
Gross Profit | -37.26M |
Operating Income | -314.73M |
Net Income | -301.74M |
EBITDA | -301.23M |
EBIT | -291.88M |
Earnings Per Share (EPS) | -4.43 |
Full Income Statement Balance Sheet
The company has 77.39M in cash and 1.98M in
debt, giving a net cash position of 75.41M.
Cash & Cash Equivalents | 77.39M |
Total Debt | 1.98M |
Net Cash | 75.41M |
Retained Earnings | -606.69M |
Total Assets | 219.68M |
Working Capital | 198.21M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -167.65M
and capital expenditures -157K, giving a free cash flow of -167.8M.
Operating Cash Flow | -167.65M |
Capital Expenditures | -157K |
Free Cash Flow | -167.8M |
FCF Per Share | -2.46 |
Full Cash Flow Statement Margins
Gross margin is -42.65%, with operating and profit margins of -360.22% and -345.36%.
Gross Margin | -42.65% |
Operating Margin | -360.22% |
Pretax Margin | -345.81% |
Profit Margin | -345.36% |
EBITDA Margin | -344.77% |
EBIT Margin | -360.22% |
FCF Margin | -192.06% |